Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
NEW YORK, Feb. 14, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Tesaro, Inc. ("Tesaro") (NASDAQ:TSRO) between March 14, 2016 and January 12, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Massachusetts. To get more information go to:
http://www.zlk.com/plsra-c/tesaro-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) substantial undisclosed health risks, including anaphylaxis and anaphylactic shock, were associated with Tesaro's intravenous formulation of VARUBI (rolapitant); and (ii) as a result of the foregoing, Tesaro's shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.
On January 12, 2018, Tesaro announced it had updated the U.S. labeling of VARUBI (rolapitant) injectable emulsion packages after reports that some patients receiving the treatment experienced “Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions.”
If you suffered a loss in Tesaro you have until March 19, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
